Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...

Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Are men’s and women’s hearts that different? Yes, they are, and knowing those differences could save a woman’s life.

The venture capital arms of Pittsburgh-based UPMC and UChicago Medicine have invested in a healthcare AI startup as part of a $55 million series C funding round. UPMC Enterprises and UCM Ventures ...

A tiny implantable heart device is changing lives for patients with HFpEF heart failure. Scripps La Jolla is among 65 ...